Analyse ICON Public Limited Company (ICLR) — Kairos Score 67/100

À propos de ICON Public Limited Company

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.

Informations clés

🕴️ Activité des initiés (90 jours)

33 transactions — 0 achats et 25 ventes déclarés par les dirigeants de ICON Public Limited Company.

🏦 Hedge Funds

15 fonds institutionnels déclarent une position sur ICLR dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur ICLR.

• Is ICON a Buy as Valuation Improves but Earnings Risks Still Persist?
• ICLR Jumps 33.2% in Three Months as Recovery Expectations Strengthen

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.